1. Bonnema SJ, Hegedus L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012; 33(6):920–980.
Article
2. Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer. 2007; 109(10):1972–1979.
Article
3. Abraham P, Acharya S. Current and emerging treatment options for Graves' hyperthyroidism. Ther Clin Risk Manag. 2010; 6:29–40.
4. Lewis A, Atkinson B, Bell P, Courtney H, McCance D, Mullan K, et al. Outcome of 131I therapy in hyperthyroidism using a 550MBq fixed dose regimen. Ulster Med J. 2013; 82(2):85–88.
5. Gupta SK, McGrath S, Rogers K, Attia J, Lewis G, Viswanathan S, et al. Fixed dose (555 MBq; 15 mCi) radioiodine for the treatment of hyperthyroidism: outcome and its predictors. Intern Med J. 2010; 40(12):854–857.
Article
6. Turner J, Sadler W, Brownlie B, Rogers T. Radioiodine therapy for Graves' disease: multivariate analysis of pretreatment parameters and early outcome. Eur J Nucl Med. 1985; 11(6-7):191–193.
Article
7. Farrar JJ, Toft AD. Iodine-131 treatment of hyperthyroidism: current issues. Clin Endocrinol (Oxf). 1991; 35(3):207–212.
Article
8. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest. 1995; 25(3):186–193.
Article
9. Jarlov AE, Hegedus L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol (Oxf). 1995; 43(3):325–329.
Article
10. Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011; 21(6):593–646.
Article
11. Morris JC 3rd, Hay ID, Nelson RE, Jiang NS. Clinical utility of thyrotropin-receptor antibody assays: comparison of radioreceptor and bioassay methods. Mayo Clin Proc. 1988; 63(7):707–717.
Article
12. Moon JH, Yi KH. The diagnosis and management of hyperthyroidism in Korea: consensus report of the korean thyroid association. Endocrinol Metab (Seoul). 2013; 28(4):275–279.
Article
13. Sundaresh V, Brito JP, Thapa P, Bahn RS, Stan MN. Comparative effectiveness of treatment choices for Graves' hyperthyroidism: a historical cohort study. Thyroid. 2017; 27(4):497–505.
Article
14. Sfiligoj D, Gaberscek S, Mekjavic PJ, Pirnat E, Zaletel K. Factors influencing the success of radioiodine therapy in patients with Graves' disease. Nucl Med Commun. 2015; 36(6):560–565.
Article
15. Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf). 2004; 61(5):641–648.
Article
16. Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab. 2002; 87(3):1073–1077.
Article
17. Goolden AW, Fraser TR. Treatment of thyrotoxicosis with low doses of radioactive iodine. Br Med J. 1969; 3(5668):442–443.
Article
18. Markovic V, Eterovic D. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves' disease. J Clin Endocrinol Metab. 2007; 92(9):3547–3552.
Article
19. Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics. 2003; 111(4 Pt 1):745–749.
Article
20. de Jong JA, Verkooijen HM, Valk GD, Zelissen PM, de Keizer B. High failure rates after (131)I therapy in Graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover. Clin Nucl Med. 2013; 38(6):401–406.
Article
21. Santos RB, Romaldini JH, Ward LS. A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine ((1)(3)(1)I) doses for Graves disease treatment. Clin Nucl Med. 2012; 37(3):241–244.
Article
22. Moura-Neto A, Mosci C, Santos AO, Amorim BJ, de Lima MC, Etchebehere EC, et al. Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves' disease. Clin Nucl Med. 2012; 37(6):550–554.
Article
23. Lee HS, Min H. Iodine intake and tolerable upper intake level of iodine for Koreans. Korean J Nutr. 2011; 44(1):82–91.
Article